人工耳蜗植入治疗单侧耳聋:生活质量、每日使用时长与耳聋持续时间
该回顾性病例系列报告了2013年1月至2021年5月在本机构接受人工耳蜗植入的66例单侧耳聋成人,57例(86.4%)末次随访仍为设备使用者。设备使用者的言语识别、耳鸣、空间听觉及生活质量评分显著改善,每日佩戴时长与多项评分正相关,耳聋持续时间与言语识别无显著关联。
要点
- 66例单侧耳聋成人接受人工耳蜗植入,57例(86.4%)末次随访仍使用设备。
- 设备使用者6个月时CNC和AzBio安静下言语识别评分较术前显著提高。
- 77%患者报告耳鸣改善或消失,每日佩戴时长与多项评分正相关。
核心结论
- 数据继续支持人工耳蜗植入作为单侧耳聋的有效治疗选择。
研究设计与样本
- 回顾性病例系列,纳入2013年1月至2021年5月在本机构接受人工耳蜗植入的成人单侧耳聋患者,共66例。
主要发现
- 66例成人(中位年龄51.3岁,范围20.0-74.3岁)接受人工耳蜗植入,57例(86.4%)末次随访仍为设备使用者。
- 设备使用者CNC评分从术前8.0%提高至激活后6个月峰值45.6%(p < 0.0001)。
- 设备使用者AzBio安静下评分从术前12.2%提高至激活后6个月峰值59.5%(p < 0.0001)。
- 植入后6个月耳鸣致残量表(THI)评分从58.1降至14.6(p < 0.0001),77%患者报告耳鸣改善或消失。
- 耳聋持续时间与言语识别表现无显著差异关联;平均每日佩戴时长与CNC、AzBio评分及术后CIQOL-10评分正相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report our experience for adults undergoing cochlear implantation (CI) for single-sided deafness (SSD). METHODS: This is a retrospective case series for adults with SSD who underwent CI between January 2013 and May 2021 at our institution. CNC and AzBio speech recognition scores, Tinnitus Handicap Inventory (THI), Speech, Spatial, and Qualities of Hearing Scale (SSQ12), datalogging, and the Cochlear Implant Quality of Life (CIQOL)-10 Global measure were utilized. RESULTS: Sixty-six adults underwent CI for SSD (median 51.3 years, range 20.0-74.3 years), and 57 (86.4%) remained device users at last follow-up. Compared to pre-operative performance, device users demonstrated significant improvement in speech recognition scores and achieved peak performance at six months post-activation for CNC (8.0% increased to 45.6%, p < 0.0001) and AzBio in quiet (12.2% increased to 59.5%, p < 0.0001). THI was decreased at 6 months post-implantation (58.1-14.6, p < 0.0001), with 77% of patients reporting improved or resolved tinnitus. Patients demonstrated improved SSQ12 scores as well as the disease-specific CIQOL-10 Global questionnaire. Duration of deafness was not associated with significant differences in speech recognition performance. Average daily wear time was positively associated with CNC and AzBio scores as well as post-operative CIQOL-10 scores. CONCLUSIONS: Herein we present the largest cohort of adult CI recipients with SSD with data on speech recognition scores, tinnitus measures, and SSQ12. Novel insights regarding the correlation of datalogging, duration of deafness, and CI-specific quality of life (CIQOL-10) metrics are discussed. Data continue to support CI as an efficacious treatment option for SSD. LEVEL OF EVIDENCE: 4 Laryngoscope, 133:2362-2370, 2023.
引用
- Lindquist NR, Holder JT, Patro A, et al. Cochlear Implants for Single-Sided Deafness: Quality of Life, Daily Usage, and Duration of Deafness. Laryngoscope. 2022. PMID: 36254870. doi:10.1002/lary.30452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。